

NCT ID	NCT05215574
Title	Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Phase	Phase 1
Date Added	2022-01-31
Location	Arizona, United States California, United States Florida, United States Michigan, United States New York, United States Oklahoma, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	NGM831, NGM831 plus pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04708470
Title	Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer
Phase	Phase 1, Phase 2
Date Added	2021-01-14
Location	Maryland, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Bintrafusp alfa, Entinostat, NHS-IL12
Tags	MSS/ MMRp
NCT ID	NCT04362839
Title	Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2020-04-27
Location	California, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Ipilimumab, Nivolumab, Regorafenib, Opdivo, Stivarga, Yervoy
Tags	MSS/ MMRp
NCT ID	NCT03796884
Title	Linacotide in Treating Patients With Stages 0-3 Colorectal Cancer
Phase	Phase 2
Date Added	2019-01-08
Location	Pennsylvania, United States Washington, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Linacotide
Tags	MSS/ MMRp

NCT ID	NCT03851614
Title	Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors
Phase	Phase 2
Date Added	2019-02-22
Location	Canada
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Cediranib, durvalumab, Olaparib
Tags	MSS/ MMRp
NCT ID	NCT03832855
Title	Assessing the Immunogenicity of pING-hHER3FL
Phase	Phase 1
Date Added	2019-02-06
Location	North Carolina, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	pING-hHER3FL
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04050709
Title	QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
Phase	Phase 1
Date Added	2019-08-08
Location	California, United States
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	PD-L1 t-haNK
Tags	MSS/ MMRp
NCT ID	NCT04607421
Title	A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER)
Phase	Phase 3
Date Added	2020-10-29

Location	Arizona, United States California, United States Florida, United States Illinois, United States Louisiana, United States Minnesota, United States Missouri, United States Nebraska, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Argentina Australia Belgium Brazil Bulgaria Canada China Czechia Denmark Finland Germany India Italy Japan Korea, Republic of Mexico Netherlands New Zealand Norway Poland Russian Federation Slovakia South Africa Spain Sweden Taiwan Ukraine United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	5-FU, Bevacizumab, capecitabine, cetuximab, encorafenib, Irinotecan, Leucovorin, oxaliplatin
Tags	MSS/ MMRp
NCT ID	NCT03104439
Title	Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
Phase	Phase 2
Date Added	2017-04-07
Location	Massachusetts, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Ipilimumab, Nivolumab, Opdivo, Yervoy

Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03785249
Title	Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Phase	Phase 1, Phase 2
Date Added	2018-12-24
Location	Alabama, United States Alaska, United States Arizona, United States California, United States Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Puerto Rico
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	afatinib, cetuximab, MRTX849, Pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp